Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sex hormone synthesis is a biological process and a metabolic pathway, not a discrete molecular therapeutic target. It involves multiple enzymatic steps and numerous molecular players in a complex cascade. The process catalyzes the sequential conversions of cholesterol through intermediates such as pregnenolone, DHEA, androstenedione, testosterone, and estradiol. Key regulatory proteins, like steroidogenic acute regulatory protein (StAR), facilitate cholesterol transport. Control of this pathway occurs at the hypothalamic-pituitary-gonadal (HPG) axis through hormones including gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). Individual enzymes and receptors within this pathway, such as Aromatase (CYP19A1), 5-alpha reductase (SRD5A), 17-beta-hydroxysteroid dehydrogenase (HSD17B), estrogen receptors (ESR1, ESR2), androgen receptor, and progesterone receptor, are considered actual therapeutic targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sex hormone synthesis.